Trial · NCT02031432
Results by group104
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 104
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Event (TEAEs) | Cebranopadol | 64 | Participants | ||
| Intensity of Treatment Emergent Adverse Events | Cebranopadol | Mild intensity | 242 | Number of TEAEs | |
| Intensity of Treatment Emergent Adverse Events | Cebranopadol | Moderate intensity | 300 | Number of TEAEs | |
| Intensity of Treatment Emergent Adverse Events | Cebranopadol | Severe intensity | 119 | Number of TEAEs | |
| Changes From Baseline in the Average Pain Intensity in the Last Week During the Treatment Period | Cebranopadol | 0.8 | Standard Deviation 2.14 | units on a scale | |
| Outcome of Treatment Emergent Adverse Events (TEAE) | Cebranopadol | Recovered/resolved | 349 | Number of TEAEs | |
| Outcome of Treatment Emergent Adverse Events (TEAE) | Cebranopadol | Recovered/resolved with sequelae | 11 | Number of TEAEs | |
| Outcome of Treatment Emergent Adverse Events (TEAE) | Cebranopadol | Not recovered/not resolved | 260 | Number of TEAEs | |
| Outcome of Treatment Emergent Adverse Events (TEAE) | Cebranopadol | Recovering/resolving | 14 | Number of TEAEs | |
| Outcome of Treatment Emergent Adverse Events (TEAE) | Cebranopadol | Fatal | 11 | Number of TEAEs | |
| Outcome of Treatment Emergent Adverse Events (TEAE) | Cebranopadol | Unknown | 16 | Number of TEAEs | |
| Time to Onset of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | 53.0 | Inter-Quartile Range 19 to 106 | days | |
| Duration of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | 9.0 | Inter-Quartile Range 3 to 27 | days | |
| Causal Relationship of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | Certainly Related | 0 | Number of TEAEs | |
| Causal Relationship of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | Possibly Related | 42 | Number of TEAEs | |
| Causal Relationship of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | Probably/Likely Related | 7 | Number of TEAEs | |
| Causal Relationship of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | Unlikely Related | 37 | Number of TEAEs | |
| Causal Relationship of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | Not Related | 574 | Number of TEAEs | |
| Causal Relationship of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | Unassessable/Unclassifiable | 1 | Number of TEAEs | |
| Causal Relationship of Treatment Emergent Adverse Events (TEAEs) | Cebranopadol | Conditional/Unclassifiable | 0 | Number of TEAEs |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02031432/results